A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.5582 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 5582-5582

Author(s):

W. P. McGuire ◽

H. W. Hirte ◽

U. A. Matulonis ◽

R. T. Penson ◽

A. Husain ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Platinum Resistant

Download Full-text

Faculty Opinions recommendation of Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718128610.793486222 ◽

2013 ◽

Author(s):

David Kushner ◽

Erin Medlin

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Resistant Refractory ◽

Multicenter Phase ◽

Platinum Resistant ◽

Etirinotecan Pegol

Download Full-text

Faculty Opinions recommendation of Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718128610.793485993 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Resistant Refractory ◽

Multicenter Phase ◽

Platinum Resistant ◽

Etirinotecan Pegol

Download Full-text

A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5020 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5020-5020

Author(s):

R. E. Swensen ◽

J. Childs ◽

D. Higgins ◽

T. Gooley ◽

B. A. Goff ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gm Csf ◽

Platinum Resistant

Download Full-text

Faculty of 1000 evaluation for Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718128610.793486320 ◽

2013 ◽

Author(s):

Steve Plaxe ◽

Kristy Ward

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Resistant Refractory ◽

Multicenter Phase ◽

Platinum Resistant ◽

Etirinotecan Pegol

Download Full-text

Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, nonrandomized, multicenter, phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps254 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS254-TPS254 ◽

Author(s):

K. D. Steffensen ◽

M. Waldstr∅m ◽

B. Lund ◽

K. Bergfeldt ◽

N. Keldsen ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Wild Type ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours

European Journal of Cancer ◽

10.1016/j.ejca.2010.02.047 ◽

2010 ◽

Vol 46 (9) ◽

pp. 1573-1579 ◽

Author(s):

Helen J. Mackay ◽

Hal Hirte ◽

Terrence Colgan ◽

Al Covens ◽

Katrina MacAlpine ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Trial ◽

Platinum Resistant ◽

Deacetylase Inhibitor ◽

Ovarian Tumours

Download Full-text

Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0034-1388557 ◽

2014 ◽

Vol 74 (S 01) ◽

Author(s):

F Hilpert ◽

C Kurzeder ◽

B Schmalfeldt ◽

P Neuser ◽

N de Gregorio ◽

...

Keyword(s):

Ovarian Cancer ◽

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Multicenter Phase ◽

Platinum Resistant ◽

Recurrent Endometrial Cancer

Download Full-text

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-004-0818-x ◽

2004 ◽

Vol 54 (4) ◽

pp. 283-289 ◽

Author(s):

Robert J. Morgan ◽

Timothy W. Synold ◽

David Gandara ◽

Franco Muggia ◽

Sidney Scudder ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Recurrent Ovarian Cancer ◽

Platinum Resistant

Download Full-text

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer

British Journal of Cancer ◽

10.1038/bjc.1992.126 ◽

1992 ◽

Vol 65 (4) ◽

pp. 621-623 ◽

Author(s):

MJ Lind ◽

BMJ Cantwell ◽

MJ Millward ◽

A Robinson ◽

M Proctor ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Download Full-text